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AbstrAct
Objective The aim of this systematic review is to 
explore the association of South Asian (SA) ethnicity 
on comorbidities, microvascular and macrovascular 
complications and mortality compared with other ethnic 
groups in people with type 1 diabetes mellitus (T1DM).
Design Systematic review.
Method A systematic literature search strategy was 
designed and carried out using Medline and Embase 
for full-text and abstract studies published in English 
from 1946 to February 2016. The initial search identified 
4722 papers. We assessed 305 full-text articles in detail 
for potential inclusion. Ten papers met the inclusion 
criteria for review and an additional one paper was 
included from our secondary search strategy using the 
bibliography of included studies. In total, 11 studies 
were included.
Eligibility criteria for selecting studies Studies were 
included if they were published in English, involved SA 
participants with T1DM and compared them with non-
SA participants and assessed one of the outcomes of 
comorbidities, microvascular complications, macrovascular 
complications and mortality.
Results SA with T1DM have higher mortality compared 
with white Europeans (WE), mainly contributed to by 
excess cardiovascular disease. SA have significantly 
higher glycated haemoglobin (HbA1c), lower high-density 
lipoprotein (HDL) and lower rates of neuropathy compared 
with WE. There were no differences in rates of retinopathy 
and nephropathy. Compared with Africans, SA had lower 
levels of microalbuminuria, HbA1c and systolic blood 
pressure and higher HDL levels. There were no significant 
differences in the remaining outcomes: cardiovascular 
disease, retinopathy, neuropathy and body mass index. 
Furthermore, SA have higher HbA1c levels than Malay and 
Chinese and higher waistâ€“hip ratio and lower HDL levels 
compared with Chinese only.
Conclusion Our analysis highlights ethnic disparity in 
macrovascular outcomes that is so evident for type 2 
diabetes mellitus may also be present for SA patients 
with T1DM. We highlight the need for a large, prospective, 
cohort study exploring the effect of ethnicity in a uniform 
healthcare setting.
Background
The epidemiology of type 1 diabetes mellitus 
(T1DM) in South Asians (SA) is poorly under-
stood. Its effects on metabolic control, diabetic 
complication rate or indeed the underlying 
pathogenesis has yet to be explored. SA are 
at higher risk than white Europeans (WE) for 
the development of obesity and obesity-re-
lated diseases including insulin resistance, the 
metabolic syndrome, type 2 diabetes mellitus 
(T2DM) and coronary heart disease.1T2DM 
is two to three times more common in SA 
than in the WE population in the UK2 and 
up to three times more common among 
people of African origin.3 Furthermore, SA 
with T2DM develop the condition 5–10 years 
earlier than WE, have increased prevalence of 
diabetic complications at presentation, worse 
outcomes and die at a younger age.2 4 These 
differences have not been explored in people 
with T1DM.
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Strengths and limitations of this study
 ► The strengths of this analysis are its comprehensive 
search strategy with clearly defined population and 
outcomes.
 ► Our search strategy incorporated both full-length 
papers as well as abstracts and had a secondary 
search strategy to ensure we did not miss any 
relevant papers.
 ► We compared the South Asian (SA) group, the largest 
ethnic group globally with all other indigenous ethnic 
groups.
 ► The quality of the studies were poor with the 
majority of studies being retrospective observational 
or cross-sectional.
 ► Furthermore, the methodology of how outcomes 
were assessed was not consistently reported, and 
the numbers of SA in each study were small.
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Willi et al5 suggested that there were ethnic disparities 
in the outcomes of children with T1DM with black partic-
ipants having higher mean HbA1c levels, more diabetic 
ketoacidosis and severe hypoglycaemic events compared 
with white or Hispanic participants. A recent systematic 
review6 identified 16 studies in the current literature that 
showed racial/ethnic minority youth with T1DM having 
higher haemoglobin A1c (HbA1c) compared with Cauca-
sian youth. As the majority of these studies are conducted 
in the USA, their primary focus was on the black and 
Hispanic ethnic groups and youth with T1DM.
SA comprise 20% of the global population2 and 7% 
of the UK population.7 Furthermore, the incidence of 
T1DM appears to be similar in SA as in the background 
population.7 Therefore, there is a need to understand 
the effect of ethnicity on the progression of the disease. 
The aim of this systematic review is to explore the associ-
ation of SA ethnicity on comorbidities, microvascular and 
macrovascular complications and mortality compared 
with other ethnic groups in people with T1DM.
MeThods
Terms indicative of T1DM and SA were searched for 
in MEDLINE (Ovid) and EMBASE using keywords and 
free text. The search terms included ‘Type 1 Diabetes’, 
‘Insulin Dependent Diabetes’ and ‘South Asian’ as well 
as terms pertaining to ethnicity such as ‘ethnic or racial 
group’, ‘race’, ‘ethnic or racial aspects’ and ‘ethnic 
differences’. We also included search terms pertaining 
to the individual countries from South Asia as listed 
below. Further information on the search strategy can 
be found in online supplementary appendix 1. Full-
length papers and abstracts published in English were 
included in the search from 1946 to February 2016. 
The search was not limited to a particular study design 
or outcome and the papers did not have to be peer 
reviewed. A secondary search strategy involved reading 
bibliographies of the included studies and contacting 
authors of the included studies and committee members 
of the South Asian Health Foundation (http://www. 
sahf. org. uk) enquiring about additional studies or 
ongoing research.
The inclusion criteria were based on the Population, 
Intervention, Comparator and Outcome (PICO) frame-
work. The population was SA with T1DM including both 
children and adults. A clinical diagnosis was accepted 
for the definition of T1DM. We defined SA ethnicity as 
persons originating from the following countries: India, 
Pakistan, Sri Lanka, Bangladesh, Nepal, Bhutan and the 
Maldives, and compared their comorbidities, complica-
tions and mortality with persons of any other ethnicity 
not classified as SA. We investigated comorbidities (body 
mass index, systolic and diastolic blood pressure, HbA1c 
and lipid profile), microvascular complications (reti-
nopathy, neuropathy and nephropathy), macrovascular 
complications (ischaemic heart disease and cerebrovas-
cular disease) and cause-specific and all-cause mortality.
Identified titles and abstracts were reviewed inde-
pendently by two researchers (KS and PC). All studies 
that were deemed suitable for potential inclusion were 
then further examined in detail by the two researchers 
independently to create the final list of included studies. 
Where there were discrepancies between the two 
researchers (KS and PC) this was resolved by discussion. 
Quality assessment and data extraction was performed 
by KS and then checked by PC to identify any missing 
information (see online supplementary appendix 2). The 
Newcastle–Ottawa Quality Assessment Scale for observa-
tional studies was used for quality assessment.8
We were not able to perform a meta-analysis because 
the studies were not comparable by outcomes measured, 
were of poor quality and heterogeneous in the way SA 
ethnicity was defined. The results have been analysed 
as a narrative and presented as tabulations with textual 
description by each comorbidity and complication.
Patient involvement
Patients were not involved.
resulTs
The initial search identified 4722 papers. After removing 
duplicates (1194), the remaining 3528 titles and abstracts 
were screened. After excluding 3223 papers in this initial 
screening process, 305 full-text articles were assessed in 
detail for potential inclusion into the analysis. Ten papers 
met the inclusion criteria for review. A secondary search 
using the bibliographies of included studies yielded an 
additional one paper (figure 1). A total of 11 studies were 
therefore included: 6 studies were from the UK, 4 from 
South Africa and 1 from Malaysia. Nine of the papers 
were full-length papers and two were abstracts. Of the 
included articles, one was a prospective cohort study, 
two were retrospective analysis of observational data and 
eight studies were cross-sectional analyses. The results are 
summarised in tables 1 and 2.
resulTs
comorbidities
Body mass index
Six studies explored body mass index (BMI) and general 
weight measurements as an outcome: three comparing 
SA with WE only, one comparing with WE and Africans, 
one comparing with Africans only and one comparing to 
Malay and Chinese. The three papers comparing SA to 
only WE demonstrated no statistically significant differ-
ence in BMI.9–11 Mehta et al11 in the UK showed a mean 
BMI of 27.5 kg/m2 in SA (n=163) compared with 27.4 
in WE (n=1169) (p=0.835). Similarities in BMI (kg/m2) 
between SA and WE have previously been reported in 
two different centres (median BMI 25.6 kg/m2 vs 25.7 
kg/m2, respectively, and 30.9 kg/m2 vs 25 kg/m2, respec-
tively).9 The results were not significant due to the small 
number of participants. Shenoy et al10 also in the UK 
showed no statistically significant differences in the rates 
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Figure 1 Flowchart demonstrating study selection.
of overweight or obesity between WE (n=112) and SA 
(n=38) children with T1DM at any age grouping.
Brabarupan et al12 in the UK showed no statistically 
significant difference in BMI in SA (n=39) compared 
with WE (n=565) and Africans (n=38) (median 25.3 kg/
m2 vs 25.0 kg/m2 vs 25.7 kg/m2, respectively). Omar et 
al13 in South Africa also showed no difference between SA 
(n=40) and Africans (n=86) in mean % ideal body weight 
(91 kg/m2 vs 106 kg/m2, respectively).
Lastly, a study by Ismail et al14 in Malaysia showed that 
there was no difference in BMI when comparing SA to 
Malay and Chinese (mean 22.0 kg/m2 vs 22.3 kg/m2 vs 
22.0 kg/m2, respectively). However, there were significant 
differences in waist–hip ratio between the ethnic group 
males with SA having significantly higher waist–hip ratio 
compared with Chinese (mean 0.88 vs 0.84, respectively, 
p=0.007).
In summary, there are no demonstrable differences 
in BMI between SA, WE and African ethnic groups with 
T1DM. However, SA males compared with Chinese males 
with T1DM had a higher waist–hip ratio.
Glycaemic control
Seven studies explored glycaemic control as an outcome: 
three comparing SA with WE only, two comparing with 
WE and Africans, one comparing to Africans only and 
one comparing with Malay and Chinese. Mehta et al11 in 
the UK, demonstrated higher HbA1c levels in SA (n=163) 
(mean 9.1%) compared with WE (n=1169) (mean 8.5%) 
(p<0.001). This is similar to the results from Brabarupan 
et al12 in the UK who demonstrate SA (n=39) having 
higher HbA1c levels (median 8.3%) compared with WE 
(n=565) (median 8.0) but lower than African (n=38) 
(median 9.1) (p<0.05). Another UK study analysed SA 
and WE at two different hospitals9 and demonstrated 
similar HbA1c (median 9.0% vs 9.1%, respectively, and 
8.2% vs 8.6%, respectively, at the two different hospitals). 
Shenoy et al in10 the UK found no significant difference 
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Table 2 Summary of findings
Findings in the SASA population when 
compared with the specified ethnicity
(eg, SA have the same BMI as WE but 
higher HbA1c)
WE African Chinese
BMI → →
HbA1c ↑ ↓ ↑
SBP ↓ ↓
DBP → →
HDL ↓ ↑ ↓
Total 
cholesterol
→ → →
Retinopathy → → →
Nephropathy → ↓
Neuropathy ↓ →
CVD → →
Mortality ↑
BMI, body mass index; CVD, cardiovascular disease; DBP, 
diastolic blood pressure; HbA1c, haemoglobin A1c; HDL, high-
density lipoprotein; SA, South Asian; SBP, systolic blood pressure; 
WE, white European.
in metabolic control between WE (n=112) and SA (n=38) 
children (median HbA1c 8.4% vs 8.8%, respectively). 
Thomas et al15 in South Africa also found no statistically 
significant differences between SA (n=118), WE (n=1247) 
and Africans (n=117) in HbA1c levels (8.7% vs 8.2% vs 
9.5%, respectively). A study by Asmal et al16 in South 
Africa showed that SA (n=38) had similar mean glucose 
concentrations to Africans (n=52) (15.80 mmol/L vs 
14.20 mmol/L, respectively).
Ismail et al14 in Malaysia showed that SA (n=76) have 
significantly higher HbA1c levels compared with Chinese 
(n=91) and Malay (n=102) (mean 9.3% vs 7.8% vs 9.0%, 
respectively, p<0.001).
In summary, studies suggest SA have higher HbA1c 
levels compared with WE, Malay and Chinese but lower 
than Africans.
Blood pressure
Four studies determined blood pressure/hypertension 
as an outcome: two comparing SA with WE only, one 
comparing with WE and Africans and one comparing 
to Africans only. The three papers with a WE group 
all showed that SA have lower blood pressure than the 
comparator groups. Mehta et al11 in the UK, showed a 
significantly lower systolic blood pressure in SA (n=163) 
compared with WE (n=1169) (mean value 136.4 mm Hg 
vs 141.6 mm Hg, respectively, p=0.004). However, there 
was no difference in diastolic blood pressure between SA 
(mean 75.4 mm Hg vs 75.4 mm Hg, respectively, p=0.41). 
Brabarupan et al12 in the UK also showed that SA (n=39) 
compared with WE (n=565) and Africans (n=38) had a 
lower systolic blood pressure (median 120 mm Hg vs 130 
mm Hg vs 135 mm Hg, respectively, p<0.05) and a lower 
diastolic blood pressure (median 73 mm Hg vs 75 mm 
Hg vs 80 mm Hg, respectively, p<0.05). We have previ-
ously noted that there was no significant difference in 
systolic blood pressure between SA and WE (median 121 
mm Hg vs 125 mm Hg, respectively, and 130 mm Hg vs 
131.5 mm Hg, respectively, in two different centres) in 
a UK population.9 However, we reported that SA (n=59) 
had a higher diastolic blood pressure than WE (n=118) 
(median 86 mm Hg vs 82 mm Hg, respectively, p<0.05).9 
Lastly, Omar et al17 in South Africa showed absence of 
difference between SA (n=41) and Africans (n=92) in the 
prevalence of hypertension (5% vs 4%, respectively). The 
analyses in these studies were not adjusted.
In summary, studies suggest SA have lower systolic blood 
pressure compared with WE and Africans, but there is no 
difference in the diastolic blood pressure across these 
three ethnic groups.
Lipid profile
Five studies examined differences in lipid profiles: 
two comparing SA to WE only, one comparing to WE 
and Africans, one comparing to Africans only and 
one comparing to Malay and Chinese. A UK study has 
previously shown that SA (n=80) have lower levels of 
HDL (median 1.3 mmol/L vs 1.4 mmol/L, respectively, 
p<0.05) and higher cholesterol/HDL ratio (median 3.6 
vs 3.2, respectively, p<0.05) than WE (n=160).9 There 
were no statistically significant differences in the levels of 
total cholesterol in SA compared with WE (median 4.7 
mmol/L vs 4.6 mmol/L, respectively, and 4.45 mmol/L 
vs 4.1 mmol/L, respectively). Another UK study12 also 
showed that SA (n=39) had lower levels of HDL compared 
with WE (n=565) but higher levels than Africans (n=38) 
(median 1.30 mmol/L vs 1.49 mmol/L vs 1.25 mmol/L, 
respectively, p<0.05). They also demonstrate absence of 
difference in total cholesterol levels between SA, WE and 
Africans (median 4.00 mmol/L vs 4.50 mmol/L vs 4.40 
mmol/L, respectively) and triglyceride levels (median 
1.07 mmol/L vs 0.93 mmol/L vs 0.99 mmol/L, respec-
tively). Mehta et al11 in the UK also show similar levels of 
total cholesterol in SA (n=163) (mean value 4.6 mmol/L) 
compared with WE (n=1169) (mean value 4.8 mmol/L) 
(p=0.132).
Ismail et al14 in Malaysia demonstrate that SA (n=76) 
compared with Malay (n=102) and Chinese (91) had 
no statistically significant differences in total choles-
terol levels (mean 5.74 mmol/L vs 5.58 mmol/L vs 
5.64 mmol/L, respectively) and LDL cholesterol levels 
(mean 3.89 mmol/L vs 3.48 mmol/L vs 3.52 mmol/L, 
respectively). SA had significantly lower HDL cholesterol 
compared with Chinese (mean 1.28 mmol/L vs 1.57 
mmol/L, respectively, p<0.01) and significantly higher 
triglyceride levels (mean 1.02 mmol/L vs 0.82 mmol/L, 
respectively, p<0.03). Lastly, Asmal et al16 in South Africa 
found that SA (n=38) compared with Africans (n=52) had 
no statistically significant differences in cholesterol levels 
(mean 5.17 mmol/L vs 4.78 mmol/L, respectively) and 
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triglyceride levels (2.81 mmol/L vs 2.27 mmol/L, respec-
tively).
In summary, SA have lower HDL levels compared 
with WE and Chinese but higher than Africans. SA have 
higher triglyceride levels compared with Chinese. There 
are no differences in total cholesterol between SA and 
WE, African, Malay or Chinese ethnic groups.
Microvascular disease
Retinopathy
Four studies examined retinopathy; one comparing SA 
with WE only, two comparing to WE and Africans and 
one comparing to Africans only. The most relevant study 
by Sivaprasad et al18 investigated retinopathy in T1DM 
in the UK cohort consisting of 2626 WE, 344 Africans 
and 120 SA. The mean age in this study was 39.4±16.3 
years. The study found no statistically significant differ-
ences between SA, WE and Africans with T1DM in the 
age-standardised prevalence of maculopathy (95% CI) 
(16.6% (10% to 23.2%) vs 14.1% (12.8% to 15.4%) vs 
13.1% (9.4% to 16.8%), respectively), clinically signifi-
cant macular oedema (11.2% (5.4% to 16.9%) vs 6.5% 
(5.6% to 7.4%) vs 10.0% (6.7% to 13.3%), respectively), 
sight threatening diabetic retinopathy (17.5% (10.6% 
to 24.3%) vs 12.1% (10.9% to 13.3%) vs 15.9% (11.8% 
to 20.0%), respectively) and any diabetic retinopathy 
(54.0% (44.8% to 63.2%) vs 55.0% (53.2% to 56.9%) vs 
42.8% (37.3% to 48.3%), respectively).
Thomas et al,15 in South Africa, reported that SA 
(n=118) were at increased risk of any diabetic retinop-
athy (OR 2.02, 95% CI 1.23 to 3.29) when compared with 
WE (n=1247), after adjustment for age at diagnosis, sex, 
duration of diabetes, HbA1c, hypertension and smoking 
status. Mehta et al11 in the UK showed that SA (n=163) 
compared with WE (n=1169) had decreased prevalence 
of retinopathy (38.7% vs 48.0%, respectively, p=0.025). 
Lastly, Omar et al,17 a South African study, compared SA 
(n=41) to Africans (n=92) and were unable to demon-
strate a statistically significant difference in the prevalence 
of retinopathy (22% vs 14%, respectively).
In summary, there is no difference in the prevalence of 
retinopathy between SA, WE and African ethnic groups.
Nephropathy
Five studies explored nephropathy and renal function 
as an outcome in SA with T1DM: two papers comparing 
to WE only, one comparing to WE and Africans and two 
papers comparing to Africans only. The largest study, 
by Mehta et al11 in the UK did not show any differences 
between SA (n=163) and WE (n=1169) in the prevalence 
of nephropathy (13.5% vs 10.1%, respectively, p=0.184).
In another UK study, no statistically significant differ-
ences were found between SA (n=80) and WE (n=160) 
in creatinine levels (median 76 µmol/L vs 78 µmol/L, 
respectively), albumin/creatinine ratio (median 2.4 mg/
mmol vs 2.5 mg/mmol, respectively) and eGFR (median 
97.3 mL/min/1.732 vs 91.2 mL/min/1.732, respectively).9 
Brabarupan et al12 in the UK showed no difference in the 
prevalence of microalbuminuria between SA (n=39) and 
WE (n=565) (median 1.2 mg/mmol vs 1.2 mg/mmol, 
respectively); however, Africans (n=38) had significantly 
higher levels (median 3.7 mg/mmol) (p<0.05). There 
were two studies in South Africa comparing SA to Afri-
cans. The first by Omar et al17 showed in their cohort of 
SA (n=41) and Africans (n=92), there was absence of 
difference in the prevalence of nephropathy (7% vs 3%, 
respectively). Asmal et al16 also showed no statistically rele-
vant difference between SA (n=38) and Africans (n=52) 
in creatinine levels (mean 68.90 µmol/L vs 79.40 µmol/L, 
respectively).
In summary, there is no difference in the prevalence 
of nephropathy or difference in renal function between 
SA and WE. However, in one study, SA had lower levels of 
microalbuminuria compared with Africans.
Neuropathy
Three studies included neuropathy as an outcome in SA: 
one comparing to WE only and two comparing to Africans 
only. The most relevant study, Mehta et al11 in the UK, 
showed that SA (n=163) compared with WE (n=1169) 
have a lower prevalence of neuropathy (14.7% vs 27.8%, 
respectively, p<0.001). Omar et al17 compared SA (n=41) 
to Africans (n=92) in South Africa demonstrating no 
statistically significant differences in the prevalence of 
peripheral neuropathy (32% vs 22%, respectively) and 
autonomic neuropathy (5% vs 4%, respectively). Asmal 
et al16 in South Africa showed increased prevalence of 
neuropathy in SA (n=38) compared with Africans (n=52) 
(19% vs 4%, respectively); however, no statistical tests 
were performed.
In summary, SA have lower prevalence of neuropathy 
that WE. There is no difference noted in the prevalence 
of neuropathy between SA and Africans.
Macrovascular disease
Two studies reported cardiovascular outcomes: one 
comparing to WE only and the other comparing to 
Africans only. The largest of these studies, by Mehta 
et al11 in the UK, did not show evidence of difference 
between SA (n=163) and WE (n=1169) with T1DM in 
prevalence of cardiovascular disease (15.3% vs 11.3%, 
respectively, p=0.133). Subanalysis also did not reveal 
a difference between SA and WE in ischaemic heart 
disease (12.3% vs 8.3%, respectively, p=0.093), periph-
eral vascular disease (1.8% vs 2.7%, respectively, p=0.79) 
and cerebrovascular disease (3.7% vs 1.8%, respectively, 
p=0.13). It is important to note that the mean age in the 
T1DM group was lower (mean age of SA 41.9 years and 
WE 45.3 years) compared with T2DM (mean age 59.2 
years SA and 66.2 years WE) which may have led to an 
under-representation of cardiovascular outcomes in the 
T1DM group.
A second study compared peripheral arterial disease 
between SA and Africans in South Africa. Omar et al17 
showed that none of their participants in either the SA 
(n=41) or African group (n=92) had peripheral vascular 
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disease or ischaemic heart disease. This may also be due 
to their younger cohort of patients and small sample size.
In summary, the prevalence of cardiovascular disease 
between the SA, WE and African populations do not 
differ.
Mortality
Only one study examined the association of SA ethnicity 
on mortality in people with T1DM. Swerdlow et al19 in a 
UK study investigated mortality of SA patients compared 
with the non-SA population, approximately 97% of which 
were Caucasian. The patients were followed for up to 
28 years. In their cohort of 424 SA patients there were 
27 deaths (6.4%) and in 23 326 non-SA there were 1293 
deaths (5.5%). Mortality in SA and non-SA with T1DM 
was calculated independently by comparing with the 
general population mortality using standardised mortality 
ratios (SMRs). Compared with the reference population, 
the SMR for SA patients were 3.9 (95% CI 2.0 to 6.9) in 
men and 10.1 (6.6 to 16.6) in women. The SMR for the 
corresponding non-SA were 2.7 (2.6 to 2.9) in men and 
4.0 (3.6 to 4.3) in women. No details are provided as to 
the age of death in these patients. The most common 
causes of death in SA patients were cardiovascular 
disease (29.6%) and renal disease (14.8%). The ‘other’ 
causes of death accounted for eight deaths (29.6%) and 
included septicaemia, systemic lupus erythematosus, 
bronchopneumonia, unspecified urinary tract infection 
and congenital malformation. The most common causes 
of death in non-SA were cardiovascular disease (n=474, 
36.7%) and diabetes and hypoglycaemia (n=239, 18.5%). 
There was 1 death due to neoplasm in SA (3.7%) and 89 
in non-SA (6.9%).
In summary, mortality is higher in SA with T1DM than 
non-SA when compared with the reference population in 
the UK. SA females were in particular affected, with an 
SMR that was over twice that of the non-SA female T1DM 
population. The the most common cause of death was 
cardiovascular disease.
discussion
This is the first systematic review to examine the differences 
in comorbidities, microvascular complications, macrovas-
cular complications and mortality between SA and other 
ethnic groups with T1DM. In summary (see table 2), 
mortality is higher in SA with T1DM when compared with 
a largely WE reference population. Female SA were in 
particular affected, with a SMR that was over twice that 
of the non-SA female T1DM population. The the most 
common cause of death is cardiovascular disease.
Overall, the studies suggest that cardiovascular disease 
itself is no more common in SA T1DM compared with 
WE. The study by Mehta et al11 that examined cardiovas-
cular disease most clearly, studied a population with a 
mean age in their early 40s, and is likely to be too young 
for cardiovascular disease to manifest clinically. While 
they observed a 50% higher risk of ischaemic heart 
disease (12.3% vs 8.3%) and twice the risk of cerebrovas-
cular disease (1.8% vs 3.7%) in SA compared with WE, 
the study had less than 30% power to detect a statistically 
significant difference. Some risk factors for cardiovascular 
disease appear greater in SA, with lower HDL than WE 
and the Chinese and higher HbA1c. However, the most 
powerful risk factor for cardiovascular disease of systolic 
BP is lower than in WE.
Most studies also suggest SA have higher HbA1c levels 
than WE,20 Malay and Chinese but lower than African 
ethnic groups. Despite this, rates of retinal and nephro-
pathic microvascular disease were the same as the WE 
population and some (neuropathy) even lower. There is 
an issue around competing risk however, as SA with T1DM 
may die at a younger age before developing retinopathy.
Compared with Africans, SA had lower levels of micro-
albuminuria, lower HbA1c, lower systolic blood pressure 
and higher HDL levels. There were no statistically signif-
icant differences between these two ethnic groups in the 
remaining complications: cardiovascular disease, reti-
nopathy and neuropathy. There was also no difference 
in BMI.
Weaknesses
There are several weaknesses with the analysis. The 
quality of the studies was poor with most studies being 
retrospective observational or cross-sectional. It was not 
possible to undertake a meta-analysis of the combined 
studies because the results were heterogeneous in nature.
The studies included in the analysis are derived from 
a large range of years (1981 until 2015), a time period 
during which diabetes treatment and prevention of 
complications has changed dramatically. Ideally, the anal-
ysis should specifically consider studies which compared 
the different ethnic groups during the same period of 
observation with similar standards of therapy to eliminate 
bias.
Furthermore, we accepted a clinical diagnosis for 
T1DM in the included studies. Some studies simply relied 
on coding of T1DM in their clinical systems as inclu-
sion criteria with other studies accepting a younger age 
of diagnosis (<30/35 years of age) and insulin depen-
dency as their inclusion criteria. As we did not have a 
standardised criterion for the diagnosis of T1DM for the 
included studies, it may well be that some patients with 
juvenile-onset T2DM requiring insulin treatment may 
have been wrongly coded as having T1DM.
Moreover, the papers in our review did not include 
data on medication use which makes it unclear whether 
differences in blood pressure, hbA1c and lipid profiles 
were primarily due to ethnicity or because of differences 
in medication use.
Lastly, data from patients with SA ethnicity living in 
the UK and abroad were pooled. Prevalence of T2DM is 
higher in migrant SA compared with native SA thought 
to be secondary to urbanisation and lifestyle.21 It is 
likely that prevalence and complication rates of T1DM 
would also be different in migrant and native SA and 
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therefore grouping them together may cause inaccuracy 
of reporting of the results.
strengths
The strengths of this analysis are its comprehensive search 
strategy with clearly defined population and outcomes. 
Our search strategy incorporated both full-length papers 
as well as abstracts, included all languages and had a 
secondary search strategy to ensure we did not miss any 
relevant papers. We compared the SA group, the largest 
ethnic group globally with all other indigenous ethnic 
groups.
implications
Our analysis highlights two areas. First, the ethnic 
disparity in mortality that has previously been described 
in T2DM22 is also present for SA patients with T1DM. 
This disparity is most likely due to cardiovascular disease 
but this association remains to be proven. Given the 
close association between glycaemic control with cardio-
vascular disease and excess mortality in T1D,23 and the 
higher HbA1c in the SA population, the findings of this 
systematic review call for more aggressive glycaemic 
control in the SA T1D population. Previous literature 
has demonstrated how SA have increased adiposity in 
comparison with WE and have advocated lower cut-offs 
for BMI in SA; BMI >23 kg/m2 as overweight and 
BMI >25 kg/m2 as obese.1 24 These culturally tailored 
programmes that have been attempted for T2DM may 
also be required for T1DM.25
In addition, we may require more stringent control of 
other comorbidities such as hyperlipidaemia and hyper-
tension,26 though this needs to be formally addressed. 
Second, we highlight a need for a large, ideally prospec-
tive, multinational study exploring the effect of ethnicity 
in a uniform healthcare setting. This will enable consistent 
methodology, and standardised reporting of comor-
bidities and complications such as those mentioned 
previously, but also complications such as peripheral 
vascular disease, depression and bone fractures that have 
not previously been addressed.
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